Matinas BioPharma MTNB shares are trading lower Monday after the company announced the primary endpoint did not meet statistical significance over Vascepa in its ENHANCE-IT study of LYPDISO.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.
Matinas BioPharma's stock was down 32.29% at 99 cents. The stock has a 52-week high of $22.22 and a 52-week low of 49 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
